We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

113 hedge funds and large institutions have $254M invested in BioSpecifics Technologies Corp. in 2020 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 39 increasing their positions, 42 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 42

3% less funds holding

Funds holding: 116113 (-3)

14% less capital invested

Capital invested by funds: $294M → $254M (-$40.3M)

23% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 13

Holders
113
Holders Change
-3
Holders Change %
-2.59%
% of All Funds
2.28%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
10
Increased
39
Reduced
42
Closed
13
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
EAM
26
Eagle Asset Management
Florida
$1.9M -$121K -1,962 -5%
Boston Partners
27
Boston Partners
Massachusetts
$1.86M -$565K -9,154 -21%
CIM
28
Contrarius Investment Management
Jersey
$1.81M +$2.12M +34,298 New
MCM
29
Matarin Capital Management
New York
$1.78M +$1.44M +23,252 +221%
Charles Schwab
30
Charles Schwab
California
$1.59M -$36.5K -591 -2%
N
31
Nuveen
North Carolina
$1.45M +$276K +4,475 +20%
Los Angeles Capital Management
32
Los Angeles Capital Management
California
$1.4M -$60.2K -975 -4%
MPAM
33
Monarch Partners Asset Management
Massachusetts
$1.36M +$713K +11,550 +81%
Goldman Sachs
34
Goldman Sachs
New York
$1.31M -$263K -4,264 -15%
CAM
35
ClariVest Asset Management
California
$1.29M -$64.1K -1,038 -4%
TCA
36
Transcend Capital Advisors
New Jersey
$1.25M +$178K +2,890 +14%
IP
37
Isthmus Partners
Wisconsin
$1.18M +$25.4K +411 +2%
PPA
38
Parametric Portfolio Associates
Washington
$1.14M -$307K -4,979 -19%
SGI
39
Summit Global Investments
Utah
$1.12M +$3.02K +49 +0.2%
Ameriprise
40
Ameriprise
Minnesota
$1.1M -$6.91K -112 -0.5%
Invesco
41
Invesco
Georgia
$974K -$284K -4,602 -20%
AWCI
42
Alpine Woods Capital Investors
New York
$968K +$109K +1,774 +11%
Citadel Advisors
43
Citadel Advisors
Florida
$916K -$1.1M -17,839 -51%
MAM
44
Martingale Asset Management
Massachusetts
$862K -$1.27M -20,511 -56%
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$753K +$24.7K +400 +3%
Swiss National Bank
46
Swiss National Bank
Switzerland
$692K
Cambridge Investment Research Advisors
47
Cambridge Investment Research Advisors
Iowa
$670K +$13.6K +220 +2%
SO
48
STRS Ohio
Ohio
$544K +$154K +2,500 +32%
OSAM
49
O'Shaughnessy Asset Management
Connecticut
$518K +$138K +2,228 +29%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$505K

BSTC Hedge Fund Activity: Q3 2020 in Review

113 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q3 2020, worth a combined $254M — down 14% from $294M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of BSTC and 10 opened new positions — a net loss of 3 holders — while 42 trimmed existing stakes and 39 added.

The largest buyer was LSV Asset Management, adding an estimated $3.67M. The largest seller was Russell Investments Group, cutting an estimated $5.97M.

  • 113 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q3 2020, down from 116 in Q2 2020.
  • Funds reported $254M of BioSpecifics Technologies Corp. stock for Q3 2020, down 14% quarter-over-quarter.
  • 10 funds opened new BioSpecifics Technologies Corp. positions in Q3 2020 and 13 closed out, a net change of -3 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q3 2020 was LSV Asset Management, an estimated $3.67M added.
  • The largest BioSpecifics Technologies Corp. seller in Q3 2020 was Russell Investments Group, an estimated $5.97M sold.

Based on aggregated 13F filings for Q3 2020.